

PCI Biotech



Enabling intracellular delivery

Company presentation

November 2020










IMPOTANT NOTICE AND DISCLAIMER

This presentation may contain certain forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on PCI Biotech's business, financial condition and results of operations. The terms "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "programmes", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statement. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in a forward-looking statement or affect the extent to which a particular projection is realised. Factors that could cause these differences include, but are not limited to, implementation of PCI Biotech's strategy and its ability to further grow, risks associated with the development and/or approval of PCI Biotech's products candidates, ongoing clinical trials and expected trial results, the ability to commercialise fimaporfin (Amphinex[®]), technology changes and new products in PCI Biotech's potential market and industry, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors. No assurance can be given that such expectations will prove to have been correct. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

The reservation is also made that inaccuracies or mistakes may occur in this information given about current status of the Company or its business. Any reliance on the information is at the risk of the reader, and PCI Biotech disclaims any and all liability in this respect.

PCI BIOTECH


- ▶ Enabling intracellular delivery
 - A listed (PCIB:NO) biotech company with an oncology focused pipeline
 - Photochemical internalisation (“PCI”) technology
 - One platform technology and three well differentiated assets

Programme	Indications / Therapeutics	Preclinical	Phase I	Phase II	Pivotal
 fimaCHEM	 <i>Bile duct cancer / gemcitabine</i>				
 fimaVacc	 <i>Therapeutic cancer vaccines</i>				
 fimaNAC	 <i>Nucleic acid therapeutics</i>				

PCI TECHNOLOGY

- ▶ Enabling intracellular delivery

Mode of action



- ▶ Small molecules (chemotherapeutics – **fimaCHEM**)
- ▶ Antigens (peptides/proteins – **fimaVACC**)
- ▶ Nucleic acids (mRNA, RNAi – **fimaNAc**)

Trapped therapeutic molecules are released inside cells

- The PCI technology contains the fimaporfin substance and light
- Fimaporfin is designed to localise on the inside of endosomal membranes
- Light activates fimaporfin
- Endosomal membranes inside cells are affected
- Resulting in endosomal escape of trapped therapeutic molecules


PCI TECHNOLOGY

- ▶ Broad application


The solution to a key challenge for several modalities



Enabling approved drugs to fulfil unmet local treatment need



Enhancing cellular immune responses important for therapeutic effect



Providing a delivery solution for nucleic acid therapeutics

PCI BIOTECH AT A GLANCE

► Background

- Biopharmaceutical company focusing on development and commercialisation of novel therapies for the treatment of cancer
- Leverages Photochemical Internalisation ('PCI') tech, originating from the Oslo University Hospital – the Radium Hospital
- Platform technology with three programmes targeting an attractive and growing oncology market
- Lead programme, **fima CHEM**, is a pivotal phase orphan designated (EU & US) first-in-class photochemical internalisation product for treatment of extrahepatic bile duct cancer – a disease without approved drugs

► History and milestones

2008 - 2017		2018 - 2020	
<ul style="list-style-type: none"> - Listing on Oslo Axess - Phase I study (first in man) completed, demonstrating safety and promising efficacy of fima CHEM, published in Lancet Oncology* - First patient treated Ph Ib bile duct cancer study with fima CHEM - Focus on fima VACC amplified, IP generation - First pre-clinical collaboration agreement for fima NAc 	<ul style="list-style-type: none"> - Early encouraging signs of efficacy in Phase Ib bile duct cancer study with fima CHEM - Orphan drug status in EU for fima CHEM in bile duct cancer - First subject dosed in the Phase I study with fima VACC - Further fima NAc collaborations 	<ul style="list-style-type: none"> - fima CHEM granted Orphan drug status in bile duct cancer in US - Important commercialisation guidance from regulators for fima CHEM - Promising initial clinical results for the fima VACC programme - Encouraging survival data from Ph Ib in bile duct cancer with fima CHEM 	<ul style="list-style-type: none"> - Successful transfer from Oslo Axess to Oslo Børs main list - Completion of the full Ph Ib study in fima CHEM with successful safety read-out for repeated treatment - Funding for initiation of pivotal fima CHEM study ("RELEASE") in bile duct cancer - First patient enrolled into the fima CHEM RELEASE study with registration intent - Successful PoC for fima VACC with enhanced immune responses - Important fima VACC patents for US granted - Promising response on patent application for mRNA delivery with fima NAc

Source: PCI Biotech
 * Lancet Oncology (2016) 17(9): p1217–1229

MANAGEMENT TEAM



Dr. Per Walday, CEO

- Chief Executive Officer since 2008
- Previously Global Head of Project Management at GE Healthcare
- Other experience includes manager positions in Nycomed Imaging/ Amersham Health
- Ph.D. Physiology, University of Oslo




Dr. Anders Høgset, CSO

- Chief Scientific Officer since 2001 (deputy CEO 2004-2008)
- Previously Senior Scientist at Radiumhospitalet developing the PCI technology
- Ph.D. Biochemistry, University of Oslo



Dr. Amir Snapir, CMO

- Chief Medical Officer since May 2020
- Most recently Director Rare Disease Development at Orion Pharma
- MD, Univ. of Tel Aviv, Israel
- Ph.D., Univ. of Turku, Finland



Kristin Eivindvik, CDO

- Chief Development Officer since 2018
- Formerly held the position as VP Business Operations at Alertis Medical. Other experience from GE Healthcare
- MSc. Pharmacy, University of Oslo



Ludovic Robin, CBO

- Chief Business Officer since May 2020
- Previous business development experience include pharma (Shire) and biotech (Advicenne)
- PharmD., MSc in Industrial Pharmacy; Lyon, France
- MBA, HEC Paris, France



Ronny Skuggedal, CFO

- Chief Financial Officer since 2013
- State Authorised Public Accountant Norway
- 12 years experience from auditing and advisory services, PwC
- MSc. Economics and Business Administration, NHH and Master Professional Accountancy, BI NBS

BOARD OF DIRECTORS



Dr. Hans Peter Bøhn, Chairman

- Chairman since 2016
- 12 years experience from various management positions with Nycomed Imaging
- Other experience includes being a financial analyst, covering life science companies




Dr. Christina Herder, Director

- Executive Vice President, Chief Operating Officer at Medivir AB
- Previous experience includes management positions with Modus Therapeutics and SOBI
- Board member of Idogen AB



Prof. Andrew Hughes, Director

- Strategy Director of the experimental cancer medicine at Manchester Cancer Research Centre, UK
- Broad experience from AstraZeneca, most recently Global Vice President of Early Clinical Development
- Clinical investigator on over 200 clinical trials and leading over 50 research and early development programmes



Dr. Lars Viksmoen, Director

- > 25 years broad, international experience from pharma, biotech and medtech industry
- Worked 10 years as a surgeon prior to his executive career
- Previous experience include Merck and GN ReSound



Hilde Furberg, Director

- > 35 years broad, international experience from sales, marketing, strategy and management in pharma and biotech industry
- Most recently European Head of Rare Diseases for Sanofi Genzyme
- Board member of Calliditas and Tappin

INVESTMENT HIGHLIGHTS

Broad platform technology

PCI is a platform technology with three programmes targeting an attractive and growing oncology market, with a clear path to a high unmet need orphan oncology market for the lead candidate

Advanced lead product candidate

fima CHEM – Amphinex® is an orphan designated (EU & US) first-in-class product candidate in pivotal development for treatment of bile duct cancer – a disease without approved drugs

Encouraging clinical results

Positive early signs of tumour response in a first-in-man study published in Lancet Oncology, and in a Phase I study specifically targeting bile duct cancer – encouraging survival data

Defined development strategy

Development strategy for lead candidate established based on thorough regulatory discussions with FDA and EMA – a single randomised pivotal study with accelerated/conditional approval potential

Pipeline opportunities

fima VACC – a clinical stage vaccination technology with encouraging cellular immune responses
fima NAC – a preclinical gene therapy delivery solution with established key player collaborations

Experienced leadership

Management team, Board of Directors and advisors with extensive pharmaceutical industry experience across a range of medical development and commercial areas

THREE WELL-DEFINED DEVELOPMENT PROGRAMMES

fima **CHEM**



- ▶ First-in-man study published in Lancet Oncology¹
- ▶ Encouraging efficacy data from Phase I in inoperable extrahepatic bile duct cancer
- ▶ Pivotal phase initiated, with potential for approval based on interim read
- ▶ Orphan disease with high price potential

fima **VACC**



- ▶ Expected market growth largely driven by therapeutic vaccine combinations with checkpoint inhibitors
- ▶ Features important for therapeutic cancer vaccines demonstrated in healthy volunteers
- ▶ Aim is to out-license the technology on non-/semi-exclusive basis – opportunity to develop own vaccination products

fima **NAC**




- ▶ Massive investments and high expectations for nucleic acids within the pharmaceutical industry
- ▶ Strong preclinical data set
- ▶ Research collaborations with several players
- ▶ Aim is to out-license the technology on non-/semi-exclusive basis

1) Lancet Oncology (2016) 17(9): p1217–1229

PCI TECHNOLOGY


► fima CHEM – mode of action



The intracellular trafficking of chemotherapeutics is not well characterised for many products, but it is known that endocytotic uptake and/or sequestering into endosomes can lead to high endosomal concentrations.

fima CHEM can release biologically active chemotherapeutics that are trapped in endosomes, thereby enabling them to reach their target before being inactivated in lysosomes. Shown with a number of key chemotherapeutics in preclinical models.

Chemotherapeutics



FIRST-IN-MAN STUDY PUBLISHED IN LANCET ONCOLOGY¹

▶ With independent expert commentary²

Articles

Disulfonated tetraphenyl chlorin (TPCS_{2a})-induced photochemical internalisation of bleomycin in patients with solid malignancies: a phase 1, dose-escalation, first-in-man trial

Ahmed A Sultan*, Wicsson Jorjén*, Kristian Berg, Anders Hagret, Charles A Mossa, Rifat Hamoudi, Zaid Hammad, Colin Simons, Dawn Carnell, Martin Foster, Colin Hoppe

Summary
Background Photochemical internalisation, a novel minimally invasive treatment, has shown promise in enhancing and site-directing the effect of anticancer drugs by administration of chemotherapy release. We assessed the safety and tolerability of a newly developed photochemical tetraphenyl chlorin (TPCS_{2a}) in mediating photochemical internalisations of bleomycin in patients with recurrent solid malignancies.

Methods In this phase 1, dose-escalation, first-in-man trial, we recruited patients (aged 18 to 80 years) with recurrent, advanced, or metastatic cutaneous or subcutaneous malignancies who were initially treated with bleomycin chemotherapy from a single centre in the UK. Patients were given TPCS_{2a} on day 0, followed by a fixed dose of 15 000 IU/m² bleomycin by intravenous infusion on day 1. The primary tumour was illuminated with 652 nm laser light (flash at 60 J/cm²). The primary endpoint was safety and tolerability of TPCS_{2a} in successive dose cohorts and maximum tolerated dose. The primary analysis was per protocol. The study is registered with ClinicalTrials.gov, NCT00993312, and has been completed.

Findings Between Oct 3, 2009, and Jan 14, 2014, we recruited 22 patients into the trial. 12 patients completed the 3-month follow-up period. Adverse events related to photochemical internalisation were limited to the local inflammatory process, or systemic, mostly as a result of the skin-photosensitising effect of TPCS_{2a}. Common grade 3 or worse adverse events were unexpected higher transient skin photosensitivity (grade 4) noted in two patients at a TPCS_{2a} dose of 1.5 mg/kg (skin photosensitivity [grade 2]), dose-limiting toxicity was reported in the 1.0 mg/kg cohort (skin photosensitivity [grade 2]). No deaths related to photochemical internalisation were reported. The maximum tolerated dose of TPCS_{2a} was 1.0 mg/kg. Administration of TPCS_{2a} was found to be safe and tolerable by all patients. No deaths related to photochemical internalisation treatment.

Interpretation TPCS_{2a}-mediated photochemical internalisation of bleomycin is safe and tolerable. We identified TPCS_{2a}, 0–25 mg/kg as the recommended treatment dose for future trials.

Funding PCI Biotech.

Introduction
Photochemical internalisation is a novel technology that facilitates the delivery of therapeutic molecules into the cytosol of cells. It was developed to enhance targeted intracellular delivery of therapeutics that are not able to penetrate cellular membranes, including proteins, nucleic acids, and various nanoparticles, and some small molecule chemical entities. These molecules are taken up into cells by endocytosis and accumulate in endosomes and lysosomes where they are trapped or degraded and are therefore unable to exert their therapeutic potential. Photochemical internalisation aims to overcome this hurdle by the use of highly amphiphilic photosensitisers that are trapped in the same endocytic vesicles as the therapeutics. Upon exposure to light of appropriate wavelength, reactive oxygen species are induced, rupturing the membranes and lysosomes, thereby releasing the therapeutic contents into the cytosol and allowing the drugs to reach their targets. By site-directed illumination, photochemical internalisation can be used to target drugs preferentially to tumour sites, reducing side-effects in distant normal tissues. The mechanism and practical application of photochemical internalisation was initially described in preclinical models by Berg and colleagues¹ in 1999, highlighting its potential clinical usefulness in delivering cancer therapy gene therapy and vaccination. Results from an in-vitro investigation showed that photochemical internalisation can enhance cellular uptake of chemotherapeutic agents, such as bleomycin, especially those that do not easily cross cellular membranes.¹⁴ In-vitro studies¹⁴ of photochemical

Comment

Photochemical internalisation for solid malignancies

Photochemical internalisation is a light-based therapeutic approach that has shown promise for enhancing the efficacy of a range of macromolecules including targeted proteins, genes, and chemotherapeutics.¹ It is a special case of photodynamic therapy, which has been approved for several cancer and non-cancer indications.² In photodynamic therapy, cytotoxicity results from interactions between a photosensitiser and light in the presence of oxygen. Since damage to healthy tissue is minimal following photodynamic therapy,² excellent cosmetic effects are typically seen, which makes this type of treatment well suited for the treatment of early lesions and palliation of advanced disease.

to the effects seen with ionising radiation. In studies using selective electroporation of the plasma membrane, a 100-times increase in bleomycin toxicity has been reported,³ thereby providing the rationale for the photochemical internalisation approach in which membrane-bound photosensitisers.

In The Lancet Oncology, Ahmed Sultan and colleagues⁴ present the first clinical study to assess the safety and tolerability of photochemical internalisation for enhancing the efficacy of bleomycin in patients with recurrent solid malignancies. The results of this phase 1 first-in-man dose-escalation trial of a new TPCS_{2a}-mediated treatment approach seem to be encouraging. Of particular interest are the findings that TPCS_{2a} treatment was well tolerated in patients with recurrent solid malignancies, including head and neck cancer, across all dose cohorts, and that the maximum tolerated dose of TPCS_{2a} was 1.0 mg/kg. Moreover, and progressive disease was reported in two (11%) patients, and no deaths related to TPCS_{2a} treatment were reported. The authors report that the maximum tolerated dose of TPCS_{2a} was 1.0 mg/kg (skin photosensitivity [grade 2]), dose-limiting toxicity was reported in the 1.0 mg/kg cohort (skin photosensitivity [grade 2]). No deaths related to photochemical internalisation were reported. The authors conclude that TPCS_{2a}-mediated photochemical internalisation of bleomycin is safe and tolerable. We identified TPCS_{2a}, 0–25 mg/kg as the recommended treatment dose for future trials.


Photochemical internalisation for solid malignancies is a potential limitation of radiotherapy, is it is unlikely to result in successful control of multiple lymphatic metastases and, as such, it is ill suited as a primary treatment modality in most patients with head and neck cancer. Even so, photochemical internalisation could have a role as a primary palliative treatment and in the treatment of patients with early cancers who are at fairly low risk of nodal metastases.

“The results of this phase 1, first-in-man, dose-escalation trial... ..are encouraging. Overall, the results... ..suggest that photochemical internalization might have a role in the treatment of early lesions and palliation of advanced disease... These findings provide the basis for further studies.”

¹ Sultan et al (2016) Lancet Oncology 17(9):1217-1229
² Madsen (2016) Lancet Oncology 17(9):1173-1174

BILE DUCT CANCER (CHOLANGIOCARCINOMA, CCA)

- ▶ Life threatening and poor outcomes
 - ▶ **Survival: Poor Prognosis**
 - 5 years survival (Europe), 5% to 17% depending on CCA¹
 - ▶ **Cholangiocarcinoma includes:**
 - Intra-hepatic tumours (iCCA): 10%¹
 - Extra-hepatic tumours (eCCA)
 - Perihilar/Klatskin tumours, (pCCA): 60-70%¹
 - Distal tumours dCCA: 20-30%¹
 - ▶ **Classification based on different evolving systems²:**
 - Primary tumours, localisation, size/number, accessibility, vascular invasion
 - Regional lymphatic nodes and distant metastasis
 - ▶ **Diagnosis: no straightforward clinical features**
 - Peak age for CCA is the seventh decade
 - Late stage and rapid deterioration



© 2013 Tereese Winslow LLC
U.S. Govt. has certain rights

Perihilar bile duct cancer is the main target for PCI treatment

BILE DUCT CANCER

▶ A population well segmented

▶ **fimaCHEM : A clear Medical positioning**¹

- First line treatment for inoperable extrahepatic CCA

▶ **Incidence rate**²:


- US CCA: 1.6/100,000 /year; extrahepatic CCA: 0.86/100,000/year
- EU5 CCA: 2.4/100,000/year; extrahepatic CCA: 1.4/100,000/year

▶ **Resectable CCA**³:

- Less than one-third of the patients are classified as having a resectable tumour at the time of diagnosis

▶ **fimaCHEM estimated eligible population**⁴:

- US & Europe: approx. 3,000 patients/year
- Asia: >4,000 patients/year



1) ISMO clinical practices guidelines, 2016 2) Rarecare project 3) Banales & coll, experts consensus document,(ENS-CCA), 2016 4) PCIB internal analysis

fima CHEM

- ▶ An excellent fit with medical need and existing treatments
- ▶ **Efficacy:** mOS¹ of **22.8 months** at selected dose (cohort IV) in Phase I dose-escalation (vs. **11-12 months**² with SoC for inoperable CCA treatments)
- ▶ **Easy to use:** Illumination through standard endoscopic methods compatible with endoscopic stenting for palliative biliary drainage
- ▶ **Positioning:** Enhances recommended first-line chemotherapy and boosts effect locally, where it is most needed
- ▶ **Protection:** Granted EU and US Orphan Drug designation offers 7 to 10 years exclusivity
- ▶ **Competition:** Precision/gene/small molecules in clinical development are mainly iCCA targeted or second line
- ▶ **Premium price:** Mean price for OD in the US is \$K150 (median \$K109)³

BILE DUCT CANCER – PHASE I STUDY


- ▶ Safety and pivotal dose established in Phase I
- ▶ Dose escalation with one **fimaCHEM** treatment, followed by an extension part for safety of two **fimaCHEM** treatments

Dose escalation part (N=16)

- ▶ Standard 3+3 design, with one **fimaCHEM** treatment
- ▶ 4 dose escalation cohorts
- ▶ No Dose-Limiting Toxicity (DLT) were observed
- ▶ No unexpected safety concerns
- ▶ Serious Adverse Events (SAEs) primarily cholangitis, similar to the frequency, severity and pattern reported in the literature for perihilar bile duct cancer
- ▶ Transient light sensitivity from **fimaCHEM** treatment considered acceptable in context of the encouraging efficacy results


Extension part (N=7)

- ▶ Explored safety of two **fimaCHEM** treatments (N=5)
- ▶ Same dose as dose escalation cohort IV, but up to two treatments
- ▶ No new safety signals



BILE DUCT CANCER – PHASE I RESULTS

- ▶ Best Overall Response - patients with measurable disease in all cohorts (N=15)
 - ▶ Dominated by significant target tumour reduction in the first 6 months
 - ▶ >20% reduction in tumour size was observed in 17 out of the 19 identified target lesions in cohorts 3 and 4 at 6 months; of these, 12 lesions had become undetectable (centralised read)



^a mOS – median overall survival

BILE DUCT CANCER – PHASE I DOSE-ESCALATION STUDY


- ▶ Positive early signs of efficacy – median Overall Survival of 22.8 months at selected dose

Parameters	Cohort IV (N=6)	Phase I – all dose-escalation cohorts (N=16)
Objective Response Rate (ORR)	3/5 patients (2 PR; 1 CR)	4/12 patients (2 PR; 2 CR)
Median Overall Survival (mOS)	22.8 months	16.1 months

- Encouraging tumour response and survival in Cohort IV
- Half of the patients in Cohort IV survived >30 months
- Cohort IV dose has been selected for the pivotal RELEASE study
- Results paved the way for a study with interim analysis for potential accelerated approval
- Safety of two treatments explored in a Phase I Extension – up to two treatments allowed in RELEASE

BILE DUCT CANCER – RELEASE STUDY


- ▶ Pivotal study with potential accelerated/conditional approval based on interim analysis



- Rare disease, more common in Asia
- No approved treatment
- Limited development pipeline

- >50 clinical sites in EU, Asia & US
- 12 European countries, 2 Asian + USA

- **fimaCHEM** in addition to current Standard of Care
- A three-step treatment procedure
- Up to two **fimaCHEM** treatments



BILE DUCT CANCER – RELEASE STUDY

► Endpoints, milestones and timelines

Endpoints:

Interim analysis: Primary Endpoint: Objective Response Rate (ORR)	• Orphan drug designation in EU & USA – potential accelerated approval
Final analysis: Primary endpoint: Progression free survival (PFS) Key secondary endpoint: Overall survival (OS)	• Single randomised trial considered sufficient based on interaction with US and EU regulatory authorities

Milestones and timelines:


First patient enrolled in Europe in May 2019 and in Asia in October 2020	• First patient in the US expected 1H 2021
Seamless safety review by IDMC when 8 patients have undergone two fimaCHEM treatments plus regular reviews (but no formal futility stop)	• IDMC = Independent Data Monitoring Committee
Interim analysis of 12-weeks follow-up data from 120 enrolled patients	• Interim analysis expected 2H 2022 – 1H 2023 (tbd pending further development of the COVID-19 pandemic)
Timing and format for study conclusion may be impacted by outcome of Interim analysis	• Final analysis expected approximately 2024 (tbd pending further development of the COVID-19 pandemic)

BILE DUCT CANCER – RELEASE STUDY

- ▶ Pivotal study progress by October 2020
 - ▶ Regulatory and ethics received for South Korea, Taiwan, USA and 10 of 12 planned European countries
 - ▶ 45 sites open at Q3 2020 – plan to include >50 sites
 - ▶ 6 sites opened in the US
 - ▶ 9 sites opened in Asia
 - ▶ A complete picture of the consequences of the COVID-19 pandemic on study progress is not yet available
 - ▶ Initiatives with the aim to recoup delay COVID-19 induced delays
 - Eligibility criteria modifications – amendment approved in all countries and implemented at almost all sites at Q3 2020
 - Increase number of countries/sites
 - Online outreach to attract patients outside hospital networks

RELEASE communication policy:

- Quarterly updates on
 - No. of country approvals and sites open for enrolment
 - Expected timelines for major milestones
- Other key milestones in press releases
 - E.g. outcome IDMC reviews, clinical result presentations, filing etc.



COMMERCIALISATION CONSIDERATIONS LEAD CANDIDATE

Clinical trials and results

Pivotal phase orphan designated (EU & US) first-in-class product candidate for treatment of bile duct cancer – a disease without approved drugs

Promising early signs of tumour response and encouraging survival data from Phase I pave the way for a single **pivotal registration trial**

Strategy and market

fimaCHEM targeting an **attractive and growing oncology market**, with a clear path to a **high unmet need orphan oncology market**

Development strategy established based on **thorough regulatory discussions** with FDA and EMA – a single randomised pivotal study with potential **accelerated approval as 1st line treatment**

Progressing development towards the market

Broad platform technology

Encouraging clinical results

Advanced lead product candidate

Defined strategy

Pipeline opportunities

Experienced leadership

THREE WELL-DEFINED DEVELOPMENT PROGRAMMES

fima *CHEM*



- ▶ First-in-man study published in Lancet Oncology¹
- ▶ Encouraging efficacy data from Phase I in inoperable extrahepatic bile duct cancer
- ▶ Pivotal phase initiated, with potential for approval based on interim read
- ▶ Orphan disease with high price potential

fima *VACC*



- ▶ Expected market growth largely driven by therapeutic vaccine combinations with checkpoint inhibitors
- ▶ Features important for therapeutic cancer vaccines demonstrated in healthy volunteers
- ▶ Aim is to out-license the technology on non-/semi-exclusive basis – opportunity to develop own vaccination products


fima *NAC*



- ▶ Massive investments and high expectations for nucleic acids within the pharmaceutical industry
- ▶ Strong preclinical data set
- ▶ Research collaborations with several players
- ▶ Aim is to out-license the technology on non-/semi-exclusive basis

PCI VACCINATION TECHNOLOGY – MODE OF ACTION


► fima VACC – vaccination technology



Vaccine antigens are normally presented on MHC class II by dendritic immune cells, which in most instances generates a proper immune response for prophylactic vaccination.

By releasing the trapped antigens into the cell the innovative **fima VACC** technology reroute and enhance the presentation of antigens by the immune cells to MHC class I, which generates a proper immune response for therapeutic vaccination.

Therapeutic immune response is of importance for all cancer vaccines, and vaccines targeting chronic infections.



PCI VACCINATION TECHNOLOGY – STRONG POTENTIAL

- ▶ Opportunity to play a key role in enhancing cellular immune response
 - ▶ Unique mode of action for CD8 T-cell induction
 - CD8 induction by MHC class I antigen presentation in dendritic cells and macrophages
 - ▶ Broad applicability
 - Peptide and protein antigens - prophylactic & therapeutic vaccination
 - ▶ Excellent stability of fimaporfin
 - Stable at room temperature in solution and can be autoclaved
 - ▶ Strong preclinical data set
 - Clear understanding of mode of action for CD8 induction
 - ▶ Completed Phase I clinical study with more than 90 healthy volunteers
 - Safety of intradermal administration established across a wide range of doses
 - Successful clinical proof of concept



Enhancing cellular immune responses important for therapeutic effect


STRONGLY ENHANCES VACCINATION EFFECTS

- ▶ Impressive results in relevant animal models

Cytotoxic (CD8) T-cells


- Most important immune cells to fight tumours and difficult to induce with vaccination
- **fima VACC** strongly enhances the ability of vaccines to induce CD8 T-cells

Impressive CD8 response with HPV therapeutic vaccine in mice



Source: PCI Biotech data

Therapeutic **fima VACC** vaccination with OVA in tumour model (B16-OVA melanoma/OT-1)



PHASE I STUDY IN HEALTHY VOLUNTEERS


► Overview

Main Objective:

- Determine the safety, tolerability and immune response of **fima VACC** when given as intradermal injections in combination with an adjuvant (Hiltonol) and antigens (KLH and HPV E7 peptides) in healthy subjects

Study Treatments:


- 6-12 subjects in each cohort – different doses of fimaporfin photosensitiser
- Adjuvant: Hiltonol (poly-ICLC; adjuvant), 50µg
- Control group: Adjuvant + Antigens
- **fima VACC** groups: Adjuvant + Antigens + **fima VACC**
- Intradermal injections with 2 weeks intervals (rotating injection sites)
- Light application 200 sec, 20 (± 4) hours after ID dosing




SUCCESSFUL CLINICAL PROOF-OF-CONCEPT

- ▶ Phase I study in healthy volunteers shows enhanced immune responses

Higher rate of T-cell responders



More robust CD8 T-cell responses



fima VACC provides:

- ✓ *Increased number of responders*
- ✓ *Enhanced T-cell responses*
- ✓ *Improved T-cell functionality*

Results show that **fima VACC** induces:

- Substantial increase in number of T-cell responders to HPV E7 peptides
- Clearly enhanced overall T-cell responses
- More robust CD8 T-cell responses, which are notoriously difficult to induce with E7
- Increased functionality of induced CD8 T-cells

Highly sought-after features – especially for therapeutic vaccination against cancer and chronic infections

SOLID PROGRESS OF THE **fima VACC** PROGRAMME

- ▶ Growing robust evidence
 - ▶ Positive clinical study results presented at ESMO Immuno-Oncology Congress in December 2019
 - ▶ Clinical proof of concept data to be published in scientific journal (in progress)
 - ▶ Next step: moving to Phase II with a partner or by ourselves (proof-of-concept in disease setting)



Patented disposable "band-aid-like" device for user-friendly illumination of the vaccination site

THREE WELL-DEFINED DEVELOPMENT PROGRAMMES

fima *CHEM*



- ▶ First-in-man study published in Lancet Oncology¹
- ▶ Encouraging efficacy data from Phase I in inoperable extrahepatic bile duct cancer
- ▶ Pivotal phase initiated, with potential for approval based on interim read
- ▶ Orphan disease with high price potential

fima *VACC*



- ▶ Expected market growth largely driven by therapeutic vaccine combinations with checkpoint inhibitors
- ▶ Features important for therapeutic cancer vaccines demonstrated in healthy volunteers
- ▶ Aim is to out-license the technology on non-/semi-exclusive basis – opportunity to develop own vaccination products

fima *NAC*




- ▶ Massive investments and high expectations for nucleic acids within the pharmaceutical industry
- ▶ Strong preclinical data set
- ▶ Research collaborations with several players
- ▶ Aim is to out-license the technology on non-/semi-exclusive basis

PCI TECHNOLOGY – MODE OF ACTION

- ▶ **fimaNAC** – mode of action

Cancer cell




● Nucleic acid therapeutic

Nucleic acid therapeutics need to enter into the inside of cells to exert their therapeutic effect. Being quite large molecules, they cannot readily pass the cell membrane, but are taken up by endocytosis and thereby trapped in endosomes.

fimaNAC efficiently deliver trapped nucleic acid therapeutics from endosomes into cells.

Nucleic acid therapeutic




Release of nucleic acid therapeutics into the cytosol enables access to the gene related processes needed for therapeutic effects, such as protein production and knockdown of gene expression


Lysosomal breakdown

ENHANCING MRNA DELIVERY

- ▶ Strongly enhances delivery of mRNA *in vivo*
 - ▶ Luciferase mRNA injected intradermally
 - ▶ 2 control sites (mRNA alone) and 2 test sites (mRNA + fimaporfin)
 - ▶ All sites illuminated simultaneously
 - ▶ Animals injected with luciferin 24 hours after illumination.



Intratumoural mRNA delivery to TC-1 HPV-induced tumours



- ▶ At best light dose (2 J) nearly 50 x enhancement as compared to naked mRNA alone

VERSATILITY OF **fimaNAC**

- ▶ Delivery of many types of nucleic acid with many different vehicles *in vitro*

Main bottleneck in the field is delivery

- ▶ **fimaNAC** can deliver many types nucleic acids
- ▶ Enhancement by **fimaNAC** is best under conditions favourable for vehicle safety
 - Low ratio of vehicle to nucleic acid
 - Low concentration of vehicle/nucleic acid complex
- ▶ Especially advantageous *in vivo*
 - Difficult to achieve a high concentration of vehicle/nucleic acid complex in target cells
 - Toxicity may limit the amount of vehicle used

Nucleic acids successfully delivered by **fimaNAC**

Type of nucleic acid	Delivery vehicle
Plasmids	PEI, cationic peptides, cationic lipids, polylysine ++ Targeting to EGF-R, transferrin-R
siRNA	PEI, cationic peptides, dendrimers, lipofectamine, DOTAP, nanogels, chitosan ++
PNA (peptide nucleic acids)	None, cationic amino acids attached
mRNA	PEI, Protamine
Adenoviral vectors	None, cationic polymers
AAV vector	None

Pursuing collaboration and partnering opportunities with major players at minimal internal resources



RESEARCH COLLABORATIONS

► Four active collaborations



- Collaboration initiated 4Q 2016
- Belgian clinical biotech with proprietary TriMix platform programming dendritic cells
- Clinical programmes in melanoma and triple negative breast cancer



- Collaboration initiated 2Q 2018
- A listed Canadian clinical stage immunotherapy biotech
- Multiple clinical-stage programs in cancer and infectious diseases



- Collaboration initiated 3Q 2020
- Dutch clinical stage biotech focusing on immunotherapy and vaccines
- Multiple product candidates, with clinical programme in AML



- Collaboration initiated 3Q 2020
- Israeli biotech focusing on RNA interference (RNAi) therapy

GOOD PROGRESS AND EXCITING OUTLOOKS

fimaCHEM

Progressing development in bile duct cancer towards marketing authorisation application

- Encouraging tumour response and survival data from Phase I
- Orphan designation granted in EU and USA
- Fastest way to market determined through regulatory interactions with authorities
- Pivotal RELEASE study with interim read for accelerated approval initiated in May 2019



fimaVACC

Successful clinical PoC with enhanced immune responses

- Phase I results to be utilised in partnering efforts
- Plan for clinical proof of concept in a disease setting



fimaNAC

Collaborative strategy

- Strong preclinical data on intracellular delivery of nucleic acid therapeutics
- Research collaborations with several players in the field



RECENT KEY PUBLICATIONS

Programme	Publication	Brief summary
The PCI platform	Photochemical Internalization for Intracellular Drug Delivery. From Basic Mechanisms to Clinical Research. Jerjes W et al. J Clin Med. 2020 Feb 14;9(2):528 https://www.mdpi.com/2077-0383/9/2/528	The PCI technology has been shown to improve the biological activity of a number of macromolecules that do not readily penetrate the plasma membrane. PCI has also been found appealing for intracellular delivery of drugs incorporated into nanocarriers and for cancer vaccination.
fimaCHEM & fimaVACC	Photochemical Internalization: Light Paves Way for New Cancer Chemotherapies and Vaccines. Šošić L et al., Cancers (Basel). 2020 Jan 9;12(1):165 https://www.mdpi.com/2072-6694/12/1/165	This report describe PCI as a potential tool for cellular internalisation of chemotherapeutic agents or antigens and provides a systematic review of the ongoing research. Preclinical studies suggest that PCI can effectively be used to deliver chemotherapeutic agents to the cytosol of tumor cells and, thereby, improve treatment efficacy. Likewise, PCI was pre-clinically shown to mediate major histocompatibility complex (MHC) class I antigen presentation and generation of tumor-specific cytotoxic CD8+ T-lymphocytes (CTL) and cancer remission.
fimaCHEM	Disulfonated tetraphenyl chlorin (TPCS2a)-induced photochemical internalisation of bleomycin in patients with solid malignancies: A first-in-man phase I dose escalation clinical trial. Ahmed Sultan et al., Lancet Oncology 17 (2016),1217-1229 https://doi.org/10.1016/S1470-2045(16)30224-8	In this clinical phase I study PCI Biotech's proprietary photosensitiser fimaporfin was given at escalating doses in combination with the cytotoxic drug bleomycin to 22 patients with advanced and recurrent cancer. The treatment was found safe and tolerable, and significant anti-tumour effects were seen at all dose levels in this patient population with aggressive cutaneous and sub-cutaneous tumours.
fimaCHEM	Photochemical internalisation for solid malignancies. Steen Madsen, Comment. Lancet Oncology 17(2016),1173-1174 https://dx.doi.org/10.1016/S1470-2045(16)30274-1	The results of this phase 1 clinical study are intriguing because they suggest that photochemical internalisation might have a role in the treatment of early lesions and palliation of advanced disease.
fimaVACC	Photochemical internalization of peptide antigens provides a novel strategy to realize therapeutic cancer vaccination. Markus Haug et al., Frontiers in Immunology 9 (2018) https://doi.org/10.3389/fimmu.2018.00650	This article shows that fimaVacc can strongly enhance vaccination effects also with peptide vaccines and with cancer antigens. The article also describes the mechanism of action for fimaVacc in such vaccination.
fimaVACC	Intradermal photosensitisation facilitates stimulation of MHC class-I-restricted CD8 T-cell responses of co-administered antigen. Monika Håkerud et al., Journal of Controlled Release 174 (2014),143–150 https://doi.org/10.1016/j.jconrel.2013.11.017	The fimaVACC technology represents a potent tool for delivery of antigens to cytosol for stimulation of cytotoxic CD8+ T-cell responses after intradermal vaccination.
fimaNAC	Light-induced gene expression using messenger RNA molecules. Sigurd Bøe et al., Oligonucleotides 20 (2010),1-6 https://doi.org/10.1089/oli.2009.0209	Study to developed a site-specific delivery strategy for mRNA molecules through the use of fimaNAC. The main benefit of the strategy proposed is the possibility for protein production from the delivered mRNA in a way that is controllable in a time- and site-specific manner.

INVESTMENT HIGHLIGHTS

Broad platform technology

PCI is a platform technology with three programmes targeting an attractive and growing oncology market, with a clear path to a high unmet need orphan oncology market for the lead candidate

Advanced lead product candidate

fima CHEM – Amphinex® is an orphan designated (EU & US) first-in-class product candidate in pivotal development for treatment of bile duct cancer – a disease without approved drugs

Encouraging clinical results

Positive early signs of tumour response in a first-in-man study published in Lancet Oncology, and in a Phase I study specifically targeting bile duct cancer – encouraging survival data

Defined development strategy

Development strategy for lead candidate established based on thorough regulatory discussions with FDA and EMA – a single randomised pivotal study with accelerated/conditional approval potential

Pipeline opportunities

fima VACC – a clinical stage vaccination technology with encouraging cellular immune responses
fima NAC – a preclinical gene therapy delivery solution with established key player collaborations

Experienced leadership

Management team, Board of Directors and advisors with extensive pharmaceutical industry experience across a range of medical development and commercial areas

PCI BIOTECH HOLDING ASA

CEO Per Walday

Cell phone: +47 917 93 429

E-mail: pw@pcibiotech.com

www.pcibiotech.com

CFO Ronny Skuggedal

Cell phone: +47 940 05 757

E-mail: rs@pcibiotech.com

www.pcibiotech.com



This material has been prepared by PCI Biotech Holding ASA, or an affiliate thereof ("PCIB").

This material is for distribution only under such circumstances as may be permitted by applicable law. It has no regard to the specific investment objectives, financial situation or particular needs of any recipient. It is published solely for informational purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. No representation or warranty, either expressed or implied, is provided in relation to the accuracy, completeness or reliability of the information contained herein, nor is it intended to be a complete statement or summary of the securities, markets or developments referred to in the materials. It should not be regarded by recipients as a substitute for the exercise of their own judgement. Any opinions expressed in this material are subject to change without notice and may differ or be contrary to opinions expressed by other business areas or groups of PCIB as a result of using different assumptions and criteria. PCIB is under no obligation to update or keep current the information contained herein. PCIB, its directors, officers and employees' or clients may have or have had interests or long or short positions in the securities or other financial instruments referred to herein and may at any time make purchases and/or sales in them as principal or agent. PCIB may act or have acted as market-maker in the securities or other financial instruments discussed in this material. Furthermore, PCIB may have or have had a relationship with or may provide or has provided investment banking, capital markets and/or other financial services to the relevant companies. Neither PCIB nor any of its affiliates, nor any of PCIB's or any of its affiliates, directors, employees or agents accepts any liability for any loss or damage arising out of the use of all or any part of this material.

© 2020 PCI Biotech Holding ASA. All rights reserved. PCI Biotech Holding ASA specifically prohibits the redistribution of this material and accepts no liability whatsoever for the actions of third parties in this respect.